Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
While diabetes and obesity remain the primary targets, emerging research into new indications offers a transformational opportunity for market growth
Over the next five years, dual GIP/GLP-1 agents should migrate from second-line to first-line therapy as clinicians aim to avert tolerability limits seen with higher-dose GLP-1 monotherapy
First demonstration of the concept of bispecific antibodies
10.3390/ijms160511196 44 HrelecM.KlicekR.BrcicL.BrcicI.CvjetkoI.SeiwerthS.et al (2009)
US$ 25.84
US$ 29.81
US$ 26.64
US$ 24.30
US$ 28.47
US$ 21.83
US$ 24.24
US$ 27.13
